PTENS380T382383-E4 recognizes basal phosphorylation levels in mouse cells. Flow cytometric analysis of L929 cells secondary antibody only (blue) or 0.1 µg/mL of isotype control Cat. #2141 (orange) or of Phospho-PTEN (Ser380/Thr382/383) antibody PTENS380T382383-E4 (green). Cat. #2131.
PTEN has been identified as a tumor suppressor gene and has been found to be mutated in a significant number of human cancers, including prostate, brain, and breast cancer. PTEN shares sequence homology with the protein-tyrosine phosphatase (PTPase) family of proteins and negatively regulates the PI3K/Akt pathway. PTEN de-phosphorylates target proteins, and recombinant PTEN has been shown to have phosphoinositide 3-phosphhatase and inositol phosphate 3-phosphatase activity. Studies of primary tumor cells show a loss of PTEN expression after metastasis to the brain, via astrocyte-derived microRNAs. A cluster of phosphorylation sites (S380, T382, T383, and S385) in the C-terminal tail of PTEN drive a conformational change that reduces PTEN activity by inhibiting membrane interactions.
Predicted to work with mouse, rat, and other homologues.
Detection
Anti-Rabbit IgG
Clonality
Monoclonal
Immunogen
A synthetic phospho-peptide corresponding to residues surrounding Ser380 and Thr382/383 of human phospho PTEN
Formulation
1X PBS, 0.02% NaN3, 50% Glycerol, 0.1% BSA
Isotype
Rabbit IgGk
Preparation
Protein A+G
Recommended Usage
1µg/mL – 0.001µg/mL. It is recommended that the reagent be titrated for optimal performance for each application. See product image legends for additional information.
Storage
-20ºC
Pseudonyms
Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase, Mutated in multiple advanced cancers 1, MMAC1, Phosphatase and tensin homolog, TEP1